Infectious Diseases (all articles)
RCT | Fecal microbiota transplantation better than standard of care for first or second Clostridioides difficile infection.
26 Sep, 2022 | 12:08h | UTCFaecal microbiota transplantation for first or second Clostridioides difficile infection (EarlyFMT): a randomised, double-blind, placebo-controlled trial – The Lancet Gastroenterology & Hepatology (link to abstract – $ for full-text)
Commentary: New FMT Trial Halted Due to Effectiveness – HCP Live
Commentary from the author on Twitter (thread – click for more)
Happy (and proud) to share EarlyFMT is now published in @Lancetgashep!#FMT after vancomycin outperforms vancomycin alone for 1st or 2nd #Cdiff infection!
90% FMT vs 33% vancomycin alone.Our thoughts behind the trial journey that started 5 years ago?https://t.co/91nS2TRY6Y pic.twitter.com/sFy6G3io39
— Simon MD Baunwall (@SMDBaunwall) September 22, 2022
M-A | Antibiotics vs. no treatment for asymptomatic bacteriuria in residents of aged care facilities.
26 Sep, 2022 | 12:06h | UTCRelated:
USPSTF Recommendation Statement: Screening for Asymptomatic Bacteriuria in Adults
Diagnosis and management of Monkeypox: a review for the emergency clinician.
26 Sep, 2022 | 12:07h | UTCRelated:
Monkeypox: disease epidemiology, host immunity and clinical interventions.
Monkeypox: A clinical update for paediatricians – Journal of Pediatrics and Child Health
CDC Report | Epidemiologic and clinical characteristics of Monkeypox cases in the US.
Update on the Monkeypox Outbreak – JAMA
WHO Declares Global Public Health Emergency Over Monkeypox Virus Outbreak – Health Policy Watch
Monkeypox: A Contemporary Review for Healthcare Professionals – Open Forum Infectious Diseases
Long covid—an update for primary care.
23 Sep, 2022 | 13:10h | UTCLong covid—an update for primary care – The BMJ
RCT | Helmet noninvasive ventilation no better than usual respiratory support for acute hypoxemic respiratory failure due to COVID-19.
22 Sep, 2022 | 13:11h | UTC
Commentary on Twitter
Helmet noninvasive ventilation did not significantly reduce 28-day mortality vs usual respiratory support among patients with acute hypoxemic respiratory failure due to #COVID19 #pneumonia. https://t.co/LCuuY9UqZA #Research pic.twitter.com/NgdzwCVJ4V
— JAMA (@JAMA_current) September 20, 2022
Understanding post-COVID-19 interstitial lung disease: a new fibroinflammatory disease entity.
22 Sep, 2022 | 13:09h | UTC
Commentary on Twitter
Post #COVID19 interstitial lung disease?
🦠 PC-ILD fibroinflammatory disease
🦠 etiopathogenesis
Identifying risk factors & understanding immunopathomechanisms critical to facilitate early intervention to prevent, slow or arrest lung damage progression.
📎https://t.co/OEM2W9bAEd pic.twitter.com/m4w4qUXl9r— Intensive Care Medicine (@yourICM) September 8, 2022
Impact of routine childhood immunization in reducing vaccine-preventable diseases in the US.
21 Sep, 2022 | 13:11h | UTC
Brief Review | Source control in the management of sepsis and septic shock.
20 Sep, 2022 | 13:32h | UTCSource control in the management of sepsis and septic shock – Intensive Care Medicine (if the link is paywalled, try this one)
Commentary on Twitter
Source control to eliminate origin of infection, control contamination, restore premorbid anatomy/function in #sepsis & septic shock
🧫 think outside (abdominal) box
🧫 have multidisciplinary approach
🧫 first do NO (additional) harm#FOAMcc on @yourICM
🖇 https://t.co/GrA0oR5lf0 pic.twitter.com/ZyPaFF3qFH— Intensive Care Medicine (@yourICM) September 15, 2022
RCT | Multiple doses of prophylactic intravenous antibiotics are no better than a single dose in implant-based breast reconstruction.
19 Sep, 2022 | 12:48h | UTC
Commentary on Twitter
Multiple-dose antibiotic prophylaxis was not superior to a single-dose regimen in preventing surgical site infection and implant removal after implant-based breast reconstruction in this RCT. https://t.co/p7GbNRMPfW #OAResarch
— JAMA Network Open (@JAMANetworkOpen) September 16, 2022
M-A | Safety of single-dose primaquine as a Plasmodium falciparum gametocytocide.
19 Sep, 2022 | 12:36h | UTC
The Lancet Commission on lessons for the future from the COVID-19 pandemic – “a massive global failure.”
16 Sep, 2022 | 13:03h | UTCHomepage: The Lancet COVID-19 Commission
The Lancet Commission on lessons for the future from the COVID-19 pandemic
Editorial: COVID-19: the case for prosociality
Infographic: COVID-19 response: a massive global failure
Commentaries:
WHO responds to The Lancet COVID-19 Commission – World Health Organization
Covid-19: Commission describes “massive global failures” of pandemic response – The BMJ
Lancet Commission on COVID-19 response: ‘Massive global failure’ – CIDRAP
RCT | Among neonates with probable bacterial infection, switching from intravenous to oral antibiotics (amoxicillin–clavulanic acid) was noninferior to a full course of intravenous antibiotics and resulted in shorter hospitalization (median duration of 3.4 vs. 6.8 days).
16 Sep, 2022 | 12:59h | UTCEfficacy and safety of switching from intravenous to oral antibiotics (amoxicillin–clavulanic acid) versus a full course of intravenous antibiotics in neonates with probable bacterial infection (RAIN): a multicentre, randomised, open-label, non-inferiority trial – The Lancet Child & Adolescent Health (link to abstract – $ for full-text)
Commentary: Dutch team devise less painful ‘drip and drink’ antibiotics treatment for babies – Dutch News
Commentaries on Twitter
*New trial*—early switch to #OralAntibiotics is not inferior to full-course IV antibiotics in #neonates with probable bacterial infection; & adverse events were not increased with use of oral antibiotics
By @IKMReiss @karelallegaert & colleagues
https://t.co/2yzeh3ptuc pic.twitter.com/BgBosxfECC
— The Lancet Child & Adolescent Health (@LancetChildAdol) September 12, 2022
In term and near-term infants <28 days with probable bacterial infection, how safe is it to switch to oral Amox-Clav as opposed to completing a course of intravenous antibiotics? A new RCT in @Lancet tries to answer this question.https://t.co/M2Za54cfxF#EBNeoAlerts#NeoEBM pic.twitter.com/zKpIiW1Whx
— Evidence-Based Neo (@EBNEO) September 12, 2022
(Thread – click for more)
Efficacy & safety of switching from intravenous to oral antibiotics (amoxicillin–clavulanic acid) vs full course of IV antibiotics in neonates with probable bacterial infection (RAIN):multicentre, randomised,open-label,non-inferiority trial -The Lancet https://t.co/mcyr9bILRq
— Prof. Dr. Sanjeev Bagai (@BagaiDr) September 13, 2022
Global, regional, and national burdens of HIV and other sexually transmitted infections in adolescents and young adults aged 10–24 years from 1990 to 2019: a trend analysis based on the Global Burden of Disease Study 2019.
16 Sep, 2022 | 12:50h | UTCGlobal, regional, and national burdens of HIV and other sexually transmitted infections in adolescents and young adults aged 10–24 years from 1990 to 2019: a trend analysis based on the Global Burden of Disease Study 2019 – The Lancet Child & Adolescent Health (link to abstract – $ for full-text)
Commentary on Twitter
New analysis of #GBD data reports the global incidence of #HIV and other #STIs in adolescents and young adults https://t.co/hSjgHMGg4R pic.twitter.com/JBd7Goa9Sa
— The Lancet Child & Adolescent Health (@LancetChildAdol) September 13, 2022
RCT | Effect of different itraconazole dosing regimens on cure rates, treatment duration, safety, and relapse rates in adult patients with tinea corporis/cruris.
15 Sep, 2022 | 13:10h | UTCEffect of Different Itraconazole Dosing Regimens on Cure Rates, Treatment Duration, Safety, and Relapse Rates in Adult Patients With Tinea Corporis/Cruris: A Randomized Clinical Trial – JAMA Dermatology (free for a limited period)
Commentary on Twitter
Itraconazole is highly efficacious at all 3 doses but requires prolonged treatment, and a substantial number of patients relapsed after successful treatment. https://t.co/oOMkvp1WIp #Research pic.twitter.com/PoNYu50Cxr
— JAMA Dermatology (@JAMADerm) September 14, 2022
Systematic Review | Association of HIV infection with cardiovascular pathology based on advanced cardiovascular imaging.
15 Sep, 2022 | 13:02h | UTCAssociation of HIV Infection With Cardiovascular Pathology Based on Advanced Cardiovascular Imaging: A Systematic Review – JAMA (free for a limited period)
Editorial: HIV, Subclinical Cardiovascular Disease, and Clinical Progression: Insights From Immunologic Heterogeneity – JAMA (free for a limited period)
Study reveals the risk factors associated with infection following operative vaginal birth.
15 Sep, 2022 | 13:02h | UTC
M-A of randomized trials | In patients hospitalized with community-acquired pneumonia, corticosteroids reduce the need for mechanical ventilation without significant effects on mortality, treatment failure, or adverse events.
14 Sep, 2022 | 13:16h | UTCEffect of corticosteroids on mortality and clinical cure in community-acquired pneumonia: A systematic review, meta-analysis, and meta-regression of randomized control trials – CHEST Journal (link to abstract – $ for full-text)
Review | Multisystem inflammatory syndrome in children (MIS-C) and neonates (MIS-N) associated with COVID-19: optimizing definition and management.
14 Sep, 2022 | 13:15h | UTC
Commentary on Twitter
Proposed classification of Multisystem inflammatory syndrome in #neonates (MIS-N)
Clinical features
Treatment and immunological mechanisms#MISC #covid19 #PIMSTS #PedsICU#NeoEBM @DrSBagci #NeoTwitter #Neonatology @DrKenRemy1 @ChrisCarrollMD @lizWWyld https://t.co/tDuM51GMr4 pic.twitter.com/PNobOOzevX— Yonca Bulut M.D. (@yoncabulutmd) September 6, 2022
Under a http://creativecommons.org/licenses/by/4.0/ License
M-A | Antibiotic use in ambulatory care for acutely ill children in high-income countries.
14 Sep, 2022 | 13:10h | UTC
RCT | A double-dose influenza vaccination during hospitalization for acute coronary syndrome did not improve outcomes compared to standard-dose outpatient vaccination.
13 Sep, 2022 | 13:19h | UTC
Commentary on Twitter
In the VIP-ACS trial, among patients hospitalised with an ACS, double dose influenza vaccination before discharge does not reduce cardiovascular and pulmonary outcomes compared with standard dose vaccination 👉https://t.co/L9e7MXWfWV#EHJ #ESCCongress @ehj_ed @rladeiraslopes pic.twitter.com/95o50krrwm
— European Society of Cardiology Journals (@ESC_Journals) August 31, 2022
RCT | Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19.
13 Sep, 2022 | 13:16h | UTC
Commentaries on Twitter
Interesting results in the #PANAMO trial of vilobelimab, an anti-C5a antibody, in critically ill ICU patients w/ COVID19.
People on MV (n=386) randomized to vilobelimab vs placebo. Mortality was (maybe) reduced in a subgroup w/ more severe illness…🤔https://t.co/bO5XiRptag
1/ pic.twitter.com/EUNda67T9j— Nick Mark MD (@nickmmark) September 11, 2022
NEW Research—In addition to SOC, vilobelimab improves survival of invasive mechanically ventilated patients w/ #COVID19 and leads to a significant decrease in mortality
Read the PANAMO study from Prof Alexander Vlaar & colleagues here https://t.co/k5UuqQtqyE pic.twitter.com/Xmrb76ZpzW
— The Lancet Respiratory Medicine (@LancetRespirMed) September 8, 2022
RCT | Dipeptidyl peptidase-1 inhibition does not improve outcomes in patients hospitalized with COVID-19.
13 Sep, 2022 | 13:15h | UTC
Commentary on Twitter
NEW Research—Brensocatib treatment did not improve clinical status at day 29 in patients hospitalised with #COVID19
Being presented at #ERSCongress, ALERT 3 session, Sept 5 from 13:15 BST
From @profjdchalmers, @keirholly, @meretelong & colleagueshttps://t.co/Vlqhfs6qtj pic.twitter.com/5CY0LS4Bvy
— The Lancet Respiratory Medicine (@LancetRespirMed) September 5, 2022
Retrospective Cohort Study | Outcomes of partial oral antibiotic treatment for complicated S. aureus bacteremia in people who inject drugs.
13 Sep, 2022 | 13:09h | UTCOutcomes of Partial Oral Antibiotic Treatment for Complicated S. aureus Bacteremia in People Who Inject Drugs – Clinical Infectious Diseases (free PDF for a limited period)
Commentaries on Twitter
Interesting cohort study from @WashUID led by @LauraMarks5: IV–>PO antibiotics for PWID with Staph bacteremia associated with comparable outcomes to "standard of care" all IV, esp after 10 days of IV. Don't d/c all abx at time of discharge! @CIDJournal https://t.co/0rOfYSTnkH pic.twitter.com/yqCjifWAEK
— Paul Sax (@PaulSaxMD) September 6, 2022
🆕⚡⚡#CID @LauraMarks5
PWID w comp SA bacteremia who received oral antibiotics after an incomplete IV antibiotic(~10d) were significantly less likely to experience microbiologic failure or death than pts discharged without oral antibiotics #IDTwitter https://t.co/5zXeNfx2YL pic.twitter.com/hVhFD4iJik— Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 (@ABsteward) September 2, 2022
Review | Acute pancreatitis: diagnosis and treatment.
13 Sep, 2022 | 13:04h | UTCAcute Pancreatitis: Diagnosis and Treatment – Drugs
Commentaries:
Evidence-Based Disposition of Acute Pancreatitis – emDocs
Pancreatitis – National Institute for Health and Care Excellence
RCT | Sulopenem vs. Ciprofloxacin for the treatment of uncomplicated urinary tract infections in women.
13 Sep, 2022 | 13:00h | UTC